Compare EPR Properties (EPR) vs Cassava Sciences Inc (FLNA) Price & Performance

EPR Properties (EPR) trades at $54.08, down 2.15% today, with a bearish technical signal and oversold RSI suggesting potential reversal. The REIT maintains strong fundamentals with 91.41% gross margins and consistent dividend payments, though recent earnings showed a Q1 miss. Analyst consensus remains positive with a $65.50 price target, representing 21% upside from current levels.

EPR offers attractive income potential with a 6.5% dividend yield and diversified real estate portfolio, but faces headwinds from rising interest rates and mixed earnings performance. The stock's current valuation at 17.44 P/E appears reasonable, though technical weakness and negative cash flow projections for 2026 warrant caution for near-term investors.

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.